Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

By N. Turner, Cynthia Huang Bartlett, M. Cristofanilli. New England Journal of Medicine, 2015

660 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e6aa87ec77371cc7b51dbd158691cc114bbb3a71

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Mitchell Dowsett
2. N. Turner

In Oncology

1. J. Baselga

In Pulmonary and Respiratory Medicine

1. J. Baselga

Citations in the corpus

• Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer (2016, positive): “CDK4/6 inhibitors have shown activity in breast cancer, particularly in combination with endocrine therapy (13, 23, 29).”
• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018, neutral): “Eribulin 7 (3) 13 (7) 42 (32) 3 (2) 11 (10) 29 (34)”